Glofitamab for aggressive B-cell lymphoma with biopsy-guided treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of aggressive B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
- Your lymphoma is stage II, III, or IV (meaning it has spread from where it started).
- You have a tumor that can be safely biopsied with a needle, like in the neck, armpit, groin, or under the skin.
- Your lymphoma has progressed after standard treatment, like anthracycline-based chemo for DLBCL or anti-CD20 therapy for other types.
- You have not had certain prior treatments: CAR-T therapy within 30 days, any treatment targeting CD3 and CD20, or a stem cell or organ transplant.
- You are healthy enough for the study, with no major heart problems, active infections, or recent surgeries.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
This trial tests a drug called glofitamab (a type of immunotherapy) given as a follow-up treatment after initial therapy for people with high-risk large B-cell lymphoma. The goal is to see if it helps keep the cancer from coming back.
This study is looking at how well the drug glofitamab works in people whose diffuse large B-cell lymphoma (a common type of lymphoma) didn't respond to, or came back quickly after, their first therapy. The goal is to learn how effective and safe glofitamab is in the real world when it is added to standard care.
This study is testing how well the drug Glofitamab works when given along with standard rescue treatments for adults with B-cell Non-Hodgkin Lymphoma that has relapsed or not responded to prior therapy. The goal is to see if this combination is effective and safe in everyday medical practice.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Hear when a new Relapsed/Refractory Diffuse Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.